Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CCR10 | P46092 | 12/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397631 | 0.80 | SLC6A2 (0.34) | LMNAGLACCR10SLC6A2SLC6A4 | |
| SCHEMBL10504247 | 0.80 | CCR10 (0.36) | TGFBR1LMNAGLACCR10SLC6A2 | |
| SCHEMBL10445780 | 0.80 | CCR10 (0.36) | TGFBR1LMNAGLACCR10SLC6A2 | |
| SCHEMBL7750534 | 0.77 | ALDH1A1 (0.38) | CCR10L3MBTL1 | |
| SCHEMBL6332741 | 0.76 | HTR2C (0.45) | LMNACCR10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10504636 | 0.71 | TGFBR1 (0.36) | TGFBR1LMNAGLACCR10SLC6A2 | |
| SCHEMBL27936480 | 0.71 | ALDH1A1 (0.47) | L3MBTL1 | |
| SCHEMBL27993369 | 0.71 | LMNA (0.33) | LMNAGLACCR10SLC6A2SLC6A4 | |
| SCHEMBL83810 | 0.71 | KDM4E (0.41) | LMNAGLASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27608334 | 0.68 | LMNA (0.35) | LMNAGLACCR10SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896454-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR -SECRETASE MODULATION | Wyeth a Corporation of the State of Delaware (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005366-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |